Piper Jaffray downgraded Acceleron Pharma (NASDAQ: XLRN) from Overweight to Neutral ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Downgrades

Acceleron Pharma (XLRN) Granted FDA Orphan Drug Designation for ACE-083 in Facioscapulohumeral Muscular DystrophyJuly 12, 2018 7:10 AM Acceleron Pharma (XLRN) PT Raised to $62 at UBSJuly 10, 2018 8:01 AM Acceleron Pharma (XLRN) PT Raised to $74 at H.C. Wainwright Following Positive BELIEVE Results July 10, 2018 7:34 AM